312
Participants
Start Date
May 1, 2025
Primary Completion Date
December 1, 2027
Study Completion Date
December 31, 2027
Reamberin
Infusion of study drug REAMBERIN®, solution for infusion 1.5%, in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
Placebo
Infusion of 0,9% normal saline in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
RECRUITING
"State Budgetary Institution of Healthcare of the Arkhangelsk Region First City Clinical Hospital named after E.E. Volosevich", Arkhangelsk
RECRUITING
"Regional budgetary healthcare institution Ivanovo regional clinical hospital", Ivanovo
RECRUITING
Kuzbass Clinical Hospital of Emergency Medical Care named after M.A. Podgorbunsky, Kemerovo
POLYSAN Scientific & Technological Pharmaceutical Company
INDUSTRY